Johnson & Johnson (JNJ) closed at $161.23 in the latest trading session, marking a +1.07% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.11%. At the same time, the Dow added 0.12%, and the tech-heavy Nasdaq lost 0.41%.The world's biggest maker of health care products's shares have seen an increase of 1.76% over the last month, not keeping up with the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7%.The upcoming earnings release of Johnson & Johnson will be of great in ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team. I ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The transactio ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this world's biggest maker of health care products have returned +1.2%, compared to the Zacks S&P 500 composite's +2.9% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Johnson & Johnson falls in, has gained 3.9%. The key question now is: What cou ...

Johnson & Johnson (NYSE:JNJ) Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Hani Abouhalka - Company Group Chairman, Robotics and Digital, Johnson & Johnson MedTech Conference Call Participants Joshua Jennings - Cowen Joshua Jennings We are going to get started with our next fireside chat session. We are thrilled to be moving down the medical devices track with executive from Johnson & Johnson's MedTech business unit. We have Hani Abouhalka, Company Group Chairm ...

Johnson & Johnson (NYSE:JNJ) Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Hani Abouhalka - Company Group Chairman, Robotics and Digital, Johnson & Johnson MedTech Conference Call Participants Joshua Jennings - Cowen Joshua Jennings We are going to get started with our next fireside chat session. We are thrilled to be moving down the medical devices track with executive from Johnson & Johnson's MedTech business unit. We have Hani Abouhalka, Company Group Chairm ...

Johnson & Johnson (JNJ) announced that the FDA granted full approval to its EFGR/MET inhibitor Rybrevant (amivantamab) in non-small cell lung cancer (NSCLC) indication.Following the FDA decision, Rybrevant, in combination with chemotherapy (carboplatin-pemetrexed), is approved for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The drug was initially granted accelerated approval for a similar indication in May 2021.Alongside the FDA appro ...

Johnson & Johnson (JNJ 0.46%) is one of the top healthcare stocks in the world, with a market cap of around $390 billion. But in recent years, it hasn't exactly been known to be a top growth stock; in five years, the stock has risen by just 18%.Even if you look at the past decade, it has risen by 76%, which averages out to a compound annual rate of 5.8%, well below the S&P 500's long-run average of 10%.But Johnson & Johnson spun off its consumer health business last year in order to focus more on growth opp ...

Wall Street offers investors an assortment of pathways to make money. However, few strategies have been more successful over the long run than buying and holding dividend stocks.Last year, Hartford Funds released a report that thoroughly examined the ins and outs of dividend stocks over extended periods. In particular, a collaboration with Ned Davis Research found that income stocks averaged a 9.18% annual return over a half-century (1973-2022), with dividend growers and initiators really packing a punch (1 ...

As financial analysts know, no rule says large and long-lived companies need to be slowly growing investments. In that vein, Cantor Fitzgerald analyst Louise Chen on Feb. 20 reaffirmed her price target of $215 for Johnson & Johnson (JNJ 0.12%), suggesting that the stock could climb by as much as 33% from its current price near $161. Chen's estimate is an outlier, as the average price target of the financial analysts covering the stock is $175.But, in the context of the company being one of the world's bigge ...